Insight, China's Pharmaceutical Industry

Shanghai Henlius Secures NMPA Approval for Phase II/III HLX22 HER2 Trials, Pioneering Novel Epitope ADC Combination in Breast Cancer

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) has granted Nanjing King-friend Biochemical Pharmaceutical Co., Ltd....

Company Drug

FDA Waskyra WAS Gene Therapy First Cell-Based

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) as the first cell‑based...

Company Drug

FDA Omisirge Severe Aplastic Anemia First HSCT

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem...

Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025

Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership...

Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly‑owned subsidiary Nova Pneuma Inc. (NPI)...

Company Deals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Fineline Cube Dec 9, 2025

Zhaoke Ophthalmology (HKG: 6622) announced it has granted TSH Biopharm (TW-8432) exclusive rights to register,...

Company Drug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 9, 2025

Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...

Company Drug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that cenobamate tablets received marketing approval from China’s National Medical Products Administration...

Company Drug

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that Solriamfetol Hydrochloride Tablets received approval from China’s National Medical Products Administration...

Company Drug

Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia

Fineline Cube Dec 8, 2025

Abbisko Cayman Limited (HKG: 2256) announced preliminary results from the dose escalation phase of the...

Company Drug

Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR

Fineline Cube Dec 8, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase 1/2 data for LBL-034 in relapsed/refractory multiple...

Company Drug

Junshi Biosciences roconkibart psoriasis NMPA Acceptance

Fineline Cube Dec 8, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announces that the National Medical Products...

Company Drug

CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity

Fineline Cube Dec 8, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...

Company Drug

Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive

Fineline Cube Dec 8, 2025

Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative...

Company Medical Device

Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Reliance

Fineline Cube Dec 8, 2025

Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) announced that its expanded polytetrafluoroethylene (ePTFE) pericardial...

Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...

Company Drug

Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval

Fineline Cube Dec 8, 2025

Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...

Company Drug

Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted

Fineline Cube Dec 8, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products...

Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025

Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...

Insight, China's Pharmaceutical Industry

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Shanghai Henlius Secures NMPA Approval for Phase II/III HLX22 HER2 Trials, Pioneering Novel Epitope ADC Combination in Breast Cancer

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

FDA Waskyra WAS Gene Therapy First Cell-Based

FDA Omisirge Severe Aplastic Anemia First HSCT

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness

Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia

Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR

Junshi Biosciences roconkibart psoriasis NMPA Acceptance

CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity

Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive

Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Reliance

Shanghai Pharma X842 Deal Termination with Sinorda

Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval

Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted

Mirxes XtalPi AI Platform Targets Asian GI Cancers

You Missed

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China